The Collaboration In COPD ExaceRbatiOns (CICERO), an ERS clinical research collaboration (CRC), is an ambitious project with the overarching aim to understand and improve outcomes in severe COPD exacerbations across Europe. Education for healthcare professionals across Europe in severe exacerbations of COPD is a key aim of CICERO.
This research seminar provided the ideal platform for the launch of the educational aims of CICERO, wide engagement and discussion around key aspects of severe exacerbations, and brought together interested clinical academics from across Europe.
The aim of this research seminar was to redefine severe exacerbations of COPD, review upcoming biomarkers and identify key interventional needs. It also aims to highlight severe exacerbations as distinct events, with important differences to mild and moderate exacerbations.
Welcome and introduction
K. Vermeersch (Leuven, Belgium)
|   |
How can treatable traits be used in severe exacerbations?
M. Bafadhel (Oxford, United Kingdom)
|  |
Are severe and moderate exacerbations different entities?
T. Greulich (Marburg, Germany)
| |
How can real-world data be used to improve outcomes?
J. Quint (London, United Kingdom)
| |
Session 1: Characterisation and features of severe exacerbations of COPD - General discussion
| |
Cardiac dysfunction
M. Contoli (Ferrara, Italy)
| |
Sarcopenia and muscle dysfunction
N. Greening (Leicester, United Kingdom)
| |
Palliation and end-of-life care
D. Janssen (Horn, Netherlands)
| |
Session 2: Addressing the non-pulmonary features of hospitalisation for exacerbations of COPD - General discussion
| |
Pharmacological treatments
W. Janssens (Leuven, Belgium)
| |
Ventilation strategies during and after discharge from hospital
L. Pisani (Bologna, Italy)
| |
Rehabilitation strategies around the time of hospitalisation
S. Singh (Leicester, United kingdom)
| |
Session 3: Treatments at preventing readmission to hospital for COPD - General discussion
| |
Round table discussion of breakout sessions (20min per group)
S. Ramakrishnan (Oxford, United Kingdom), I. Gyselinck (Leuven, Belgium)
| |
What new biomarkers are on the horizon for severe exacerbations?
P. Burgel (Paris, France)
| |
What data should be collected during severe exacerbations?
F. Franssen (Maastricht, Netherlands)
| |
Session 5: New horizons for severe exacerbations of COPD - General discussion
| |
The CICERO CRC and CATALINA study
K. Vermeersch (Leuven, Belgium)
| |
Remarks, wrap-up and action points
N. Greening (Leicester, United Kingdom), W. Janssens (Leuven, Belgium), M. Bafadhel (Oxford, United Kingdom)
| |